首页> 外文期刊>Polyhedron: The International Journal for Inorganic and Organometallic Chemistry >Diruthenium(II, III) complexes of ibuprofen, aspirin, naproxen and indomethacin non-steroidal anti-inflammatory drugs: Synthesis, characterization and their effects on tumor-cell proliferation
【24h】

Diruthenium(II, III) complexes of ibuprofen, aspirin, naproxen and indomethacin non-steroidal anti-inflammatory drugs: Synthesis, characterization and their effects on tumor-cell proliferation

机译:布洛芬,阿司匹林,萘普生和吲哚美辛非甾体抗炎药的钌(II,III)复合物:合成,表征及其对肿瘤细胞增殖的影响

获取原文
获取原文并翻译 | 示例
           

摘要

[Ru-2(dNSAID)(4)Cl] and novel [Ru-2(dNSAID)(4)(H2O)(2)]PF6 complexes, where dNSAID = deprotonated carboxylate from the non-steroidal anti-inflammatory drugs (NSIDs), respectively: ibuprofen, Hibp (1) and aspirin, Hasp (2); naproxen, Hnpx (3) and indomethacin, Hind (4), have been prepared and characterized by optical spectroscopic methods. All of the compounds exhibit mixed valent Ru-2(II, III) cores where metal-metal bonds are stabilized by four drug-carboxylate bridging ligands in paddlewheel type structures. The diruthenium complexes and their parent NSAIDs showed no significant effects for Hep2 human larynx or T24/83 human bladder tumor. In contrast, the coordination of Ru-2(II,III) core led to synergistic effects that increased significantly the inhibition of C6 rat glioma proliferation in relation to the organic NSAIDs naproxen and ibuprofen, The possibility that the complexes Ru-2-ibp and Ru-2-npx may exert effects (anti-angiogenic and anti-matrix metalloprotease) that are similar to those exhibited by NAMI-A opens new horizons for in vivo C6 glioma model studies. (C) 2007 Elsevier Ltd. All rights reserved.
机译:[Ru-2(dNSAID)(4)Cl]和新型[Ru-2(dNSAID)(4)(H2O)(2)] PF6复合物,其中dNSAID =来自非甾体类抗炎药(NSIDs)的去质子化羧酸盐)分别为:布洛芬,Hibp(1)和阿司匹林,搭扣(2);萘普生Hnpx(3)和消炎痛Hind(4)已通过光谱法制备并表征。所有这些化合物均表现出混合价的Ru-2(II,III)核,其中金属-金属键通过桨轮型结构中的四个药物-羧酸桥键配体稳定。钌络合物及其母体NSAID对Hep2人喉或T24 / 83人膀胱肿瘤无明显影响。相反,Ru-2(II,III)核心的配位导致协同效应,相对于有机NSAIDs萘普生和布洛芬而言,协同作用显着增强了对C6大鼠神经胶质瘤增殖的抑制作用。 Ru-2-npx可能发挥与NAMI-A相似的作用(抗血管生成和抗基质金属蛋白酶),为体内C6胶质瘤模型研究开辟了新的前景。 (C)2007 Elsevier Ltd.保留所有权利。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号